Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Narazaciclib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HanxBio Narazaciclib AML Preclinical Study Published
    HanxBio Narazaciclib AML Preclinical Study Published

    23 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hanxbio-announces-the-publication-of-a-research-paper-in-scientific-reports-on-preclinical-evaluation-of-narazaciclib-for-the-treatment-of-acute-myeloid-leukemia-aml-302124216.html

    PR NEWSWIRE
    23 Apr 2024
    Share Share
    Onconova Therapeutics Narazaciclib Highlights Activity in Mantle Cell Lymphoma
    Onconova Therapeutics Narazaciclib Highlights Activity in Mantle Cell Lymphoma

    12 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/12/2794697/0/en/Onconova-Therapeutics-Narazaciclib-ASH-Poster-Highlights-Activity-in-Treatment-Resistant-Mantle-Cell-Lymphoma.html

    GLOBENEWSWIRE
    12 Dec 2023
    Share Share
    Onconova's Narazaciclib Data Highlights Anti-Tumor Activity v. Other CDK4/6i™s
    Onconova's Narazaciclib Data Highlights Anti-Tumor Activity v. Other CDK4/6i™s

    08 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/08/2793371/0/en/Onconova-Therapeutics-Preclinical-Narazaciclib-Data-at-SABCS-Highlights-Differentiated-Anti-Tumor-Activity-v-Other-CDK4-6i-s.html

    GLOBENEWSWIRE
    08 Dec 2023
    Share Share
    Onconova Presents Data on Narazaciclib at the 17th International Conference
    Onconova Presents Data on Narazaciclib at the 17th International Conference

    14 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/14/2688014/0/en/Onconova-Therapeutics-Presents-Preclinical-Data-on-Narazaciclib-at-the-17th-International-Conference-on-Malignant-Lymphoma.html

    GLOBENEWSWIRE
    14 Jun 2023
    Share Share
    Onconova to Participate in R&D Showcase on Narazaciclib in Endometrial Cancer
    Onconova to Participate in R&D Showcase on Narazaciclib in Endometrial Cancer

    12 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/12/2667736/0/en/Onconova-Therapeutics-to-Participate-in-Ladenburg-Thalmann-Virtual-R-D-Showcase-on-Narazaciclib-in-Endometrial-Cancer.html

    GLOBENEWSWIRE
    12 May 2023
    Share Share
    Onconova doses first patient in trial of endometrial cancer combo therapy
    Onconova doses first patient in trial of endometrial cancer combo therapy

    12 May 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/onconova-patient-cancer-combo/

    CLINICAL TRIALS ARENA
    12 May 2023
    Share Share